$COEP
Coeptis Therapeutics Holdings, Inc.

2023 Q4 Form 10-Q Financial Statement

#000168316823007828 Filed on November 09, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3 2022 Q3
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue $0.00 $0.00
YoY Change
Gross Profit $0.00 $0.00
YoY Change
Gross Profit Margin
Selling, General & Admin $2.353M $2.828M $5.491M
YoY Change -48.5% -18.76%
% of Gross Profit
Research & Development $1.013M $4.983M $20.89K
YoY Change 23758.62%
% of Gross Profit
Depreciation & Amortization $250.3K $250.0K
YoY Change -75.0%
% of Gross Profit
Operating Expenses $3.366M $7.831M $543.7K
YoY Change -90.16% 1340.5% 443.55%
Operating Profit -$7.831M -$543.7K
YoY Change 1340.49% 443.57%
Interest Expense -$192.7K $19.80K $145.8K
YoY Change -86.42% 7533.51%
% of Operating Profit
Other Income/Expense, Net -$196.9K $1.571M $92.76K
YoY Change -94.17% 1593.1% -97.83%
Pretax Income -$3.756M -$6.261M -$305.1K
YoY Change -90.0% 1952.02% -107.3%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$3.756M -$6.261M -$305.1K
YoY Change -90.0% 1952.04% -107.3%
Net Earnings / Revenue
Basic Earnings Per Share -$0.23 -$0.42
Diluted Earnings Per Share -$0.11 -$0.23 -$0.06
COMMON SHARES
Basic Shares Outstanding 34.11M shares 25.14M shares 13.46M shares
Diluted Shares Outstanding 26.65M shares 13.46M shares

Balance Sheet

Concept 2023 Q4 2023 Q3 2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.469M $1.410M $13.83K
YoY Change -61.25% 10095.23% -97.63%
Cash & Equivalents $1.469M $1.412M $13.83K
Short-Term Investments
Other Short-Term Assets $241.6K $210.0K $17.14K
YoY Change 69.71% 1125.2% -8.19%
Inventory
Prepaid Expenses $241.6K $208.1K $17.14K
Receivables $3.500M $0.00
Other Receivables $38.98K $0.00
Total Short-Term Assets $5.250M $4.120M $30.97K
YoY Change 33.18% 13206.02% -94.87%
LONG-TERM ASSETS
Property, Plant & Equipment $108.9K $11.62K
YoY Change 768.12%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $33.27M
YoY Change -56.09%
Other Assets $2.713M $3.010M
YoY Change -30.49%
Total Long-Term Assets $2.821M $3.050M $33.27M
YoY Change -29.0% -90.83% -56.09%
TOTAL ASSETS
Total Short-Term Assets $5.250M $4.120M $30.97K
Total Long-Term Assets $2.821M $3.050M $33.27M
Total Assets $8.071M $7.171M $33.30M
YoY Change 1.96% -78.47% -56.39%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.420M $482.0K $1.400M
YoY Change 1333.74% -65.58% 2913.43%
Accrued Expenses $594.0K $298.3K
YoY Change 226.38%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $160.5K
YoY Change -100.0%
Long-Term Debt Due $975.0K $830.0K
YoY Change -35.0%
Total Short-Term Liabilities $2.989M $1.616M $1.894M
YoY Change 63.98% -14.68% 3976.13%
LONG-TERM LIABILITIES
Long-Term Debt $150.0K $150.0K $0.00
YoY Change 0.0%
Other Long-Term Liabilities $618.4K $390.0K $2.700M
YoY Change -45.74% -85.56% -55.83%
Total Long-Term Liabilities $768.4K $543.1K $2.700M
YoY Change -40.42% -79.89% -55.83%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.989M $1.616M $1.894M
Total Long-Term Liabilities $768.4K $543.1K $2.700M
Total Liabilities $3.757M $2.159M $4.594M
YoY Change 20.72% -53.0% -25.41%
SHAREHOLDERS EQUITY
Retained Earnings -$87.36M -$82.98M -$4.660M
YoY Change 32.88% 1680.87%
Common Stock $3.533K $3.299K $25.00K
YoY Change 80.53% -86.8%
Preferred Stock
YoY Change
Treasury Stock (at cost) $0.00 $0.00 $0.00
YoY Change
Treasury Stock Shares
Shareholders Equity $4.314M $5.012M -$4.563M
YoY Change
Total Liabilities & Shareholders Equity $8.071M $7.171M $33.30M
YoY Change 1.96% -78.47% -56.39%

Cashflow Statement

Concept 2023 Q4 2023 Q3 2022 Q3
OPERATING ACTIVITIES
Net Income -$3.756M -$6.261M -$305.1K
YoY Change -90.0% 1952.04% -107.3%
Depreciation, Depletion And Amortization $250.3K $250.0K
YoY Change -75.0%
Cash From Operating Activities -$1.694M -$1.960M -$70.33K
YoY Change -48.85% 2686.86% 17.51%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $350.0K -$133.3K
YoY Change -362.51%
Cash From Investing Activities $350.0K -$133.3K
YoY Change -362.51% -96.71%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.751M -220.0K 133.3K
YoY Change -96.35% -265.0%
NET CHANGE
Cash From Operating Activities -1.694M -1.960M -70.33K
Cash From Investing Activities 350.0K -133.3K
Cash From Financing Activities 1.751M -220.0K 133.3K
Net Change In Cash 57.63K -1.830M -70.33K
YoY Change -97.12% 2502.02% 17.51%
FREE CASH FLOW
Cash From Operating Activities -$1.694M -$1.960M -$70.33K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001759186
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q1 us-gaap Stock Repurchased And Retired During Period Value
StockRepurchasedAndRetiredDuringPeriodValue
usd
coep Shares Issued For Conversion Of Debt
SharesIssuedForConversionOfDebt
usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39669
dei Entity Registrant Name
EntityRegistrantName
COEPTIS THERAPEUTICS HOLDINGS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-1465952
dei Entity Address Address Line1
EntityAddressAddressLine1
105 Bradford Rd
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 420
dei Entity Address City Or Town
EntityAddressCityOrTown
Wexford
dei Entity Address State Or Province
EntityAddressStateOrProvince
PA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
15090
dei City Area Code
CityAreaCode
724
dei Local Phone Number
LocalPhoneNumber
934-6467
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
34108036 shares
CY2023Q3 us-gaap Cash
Cash
1411510 usd
CY2022Q4 us-gaap Cash
Cash
3791302 usd
CY2023Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
0 usd
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
8075 usd
CY2023Q3 us-gaap Notes Receivable Net
NotesReceivableNet
2500000 usd
CY2022Q4 us-gaap Notes Receivable Net
NotesReceivableNet
0 usd
CY2023Q3 us-gaap Interest Receivable
InterestReceivable
833 usd
CY2022Q4 us-gaap Interest Receivable
InterestReceivable
0 usd
CY2023Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
208133 usd
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
142356 usd
CY2023Q3 us-gaap Assets Current
AssetsCurrent
4120476 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
3941733 usd
CY2023Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
25237 usd
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
25237 usd
CY2023Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
13622 usd
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
12695 usd
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
11615 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
12542 usd
CY2023Q3 us-gaap Prepaid Insurance
PrepaidInsurance
205833 usd
CY2022Q4 us-gaap Prepaid Insurance
PrepaidInsurance
348333 usd
CY2023Q3 coep License Right Net Of Accumulated Amortization
LicenseRightNetOfAccumulatedAmortization
2804167 usd
CY2022Q4 coep License Right Net Of Accumulated Amortization
LicenseRightNetOfAccumulatedAmortization
3554167 usd
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
28676 usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
58914 usd
CY2023Q3 us-gaap Other Assets
OtherAssets
3038676 usd
CY2022Q4 us-gaap Other Assets
OtherAssets
3961414 usd
CY2023Q3 us-gaap Assets
Assets
7170767 usd
CY2022Q4 us-gaap Assets
Assets
7915689 usd
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
482005 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
99021 usd
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
298266 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
181998 usd
CY2023Q3 us-gaap Notes Payable Current
NotesPayableCurrent
825000 usd
CY2022Q4 us-gaap Notes Payable Current
NotesPayableCurrent
1500000 usd
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
10757 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
41618 usd
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
1616028 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1822637 usd
CY2023Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
150000 usd
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
150000 usd
CY2023Q3 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
378375 usd
CY2022Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
1125000 usd
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
14723 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
14723 usd
CY2023Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
543098 usd
CY2022Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
1289723 usd
CY2023Q3 us-gaap Liabilities
Liabilities
2159126 usd
CY2022Q4 us-gaap Liabilities
Liabilities
3112360 usd
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
32991036 shares
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
32991036 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
19566839 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
19566839 shares
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
3299 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
1957 usd
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
87990247 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
70541095 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-82981905 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-65739723 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
5011641 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
4803329 usd
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
7170767 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
7915689 usd
CY2023Q3 us-gaap Revenues
Revenues
0 usd
CY2022Q3 us-gaap Revenues
Revenues
0 usd
us-gaap Revenues
Revenues
0 usd
us-gaap Revenues
Revenues
0 usd
CY2023Q3 us-gaap Cost Of Revenue
CostOfRevenue
0 usd
CY2022Q3 us-gaap Cost Of Revenue
CostOfRevenue
0 usd
us-gaap Cost Of Revenue
CostOfRevenue
0 usd
us-gaap Cost Of Revenue
CostOfRevenue
0 usd
CY2023Q3 us-gaap Gross Profit
GrossProfit
0 usd
CY2022Q3 us-gaap Gross Profit
GrossProfit
0 usd
us-gaap Gross Profit
GrossProfit
0 usd
us-gaap Gross Profit
GrossProfit
0 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4983349 usd
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
20887 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5386129 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
20887 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2815870 usd
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5488540 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12457548 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
30948831 usd
CY2023Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
12412 usd
CY2022Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
2859 usd
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
12711 usd
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
6911 usd
CY2023Q3 us-gaap Interest Expense
InterestExpense
19800 usd
CY2022Q3 us-gaap Interest Expense
InterestExpense
56423 usd
us-gaap Interest Expense
InterestExpense
93853 usd
us-gaap Interest Expense
InterestExpense
176068 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
7831431 usd
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
5568709 usd
us-gaap Operating Expenses
OperatingExpenses
17950241 usd
us-gaap Operating Expenses
OperatingExpenses
31152697 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-7831431 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-5568709 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-17950241 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-31152697 usd
CY2023Q3 us-gaap Royalty Expense
RoyaltyExpense
15000 usd
CY2022Q3 us-gaap Royalty Expense
RoyaltyExpense
80000 usd
us-gaap Royalty Expense
RoyaltyExpense
15000 usd
us-gaap Royalty Expense
RoyaltyExpense
85000 usd
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-23601 usd
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-23566 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0 usd
CY2023Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 usd
CY2022Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-3393542 usd
CY2023Q3 coep Gain Loss On Change In Fair Value Of Derivative Liability Warrants
GainLossOnChangeInFairValueOfDerivativeLiabilityWarrants
1609125 usd
CY2022Q3 coep Gain Loss On Change In Fair Value Of Derivative Liability Warrants
GainLossOnChangeInFairValueOfDerivativeLiabilityWarrants
0 usd
coep Gain Loss On Change In Fair Value Of Derivative Liability Warrants
GainLossOnChangeInFairValueOfDerivativeLiabilityWarrants
746625 usd
coep Gain Loss On Change In Fair Value Of Derivative Liability Warrants
GainLossOnChangeInFairValueOfDerivativeLiabilityWarrants
0 usd
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1570524 usd
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-80000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
708059 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-3478542 usd
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-6260907 usd
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5648709 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-17242182 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-34631239 usd
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-6260907 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-5648709 usd
us-gaap Net Income Loss
NetIncomeLoss
-17242182 usd
us-gaap Net Income Loss
NetIncomeLoss
-34631239 usd
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.23
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.23
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.42
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.42
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.75
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.75
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.66
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.66
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26650210 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
26650210 shares
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13455905 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
13455905 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
22957402 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
22957402 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13029717 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
13029717 shares
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
2350634 usd
CY2022Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1266000 usd
CY2022Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
3540000 usd
CY2022Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
110000 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
10841695 usd
CY2022Q1 coep Warrants Issued For Extinguishment Of Debt
WarrantsIssuedForExtinguishmentOfDebt
3408559 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-19179693 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
2337195 usd
CY2022Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
685485 usd
CY2022Q2 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
180000 usd
CY2022Q2 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
382500 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
8278691 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-9802837 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
2061034 usd
CY2022Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1320000 usd
CY2022Q3 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
900000 usd
CY2022Q3 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
4755824 usd
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
3355206 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-5648709 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
6743355 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
4803329 usd
CY2023Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
3116814 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
1111706 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
122391 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-7868244 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
1285996 usd
CY2023Q2 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
351000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
811500 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
113301 usd
CY2023Q2 coep Issuance Of Common Stock And Warrants Net Of Issuance Costs
IssuanceOfCommonStockAndWarrantsNetOfIssuanceCosts
3040861 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-3113031 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
2489627 usd
CY2023Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
500000 usd
CY2023Q3 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
531800 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
514819 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
113301 usd
CY2023Q3 coep Issuance Of Common Stock And Warrants Net Of Issuance Costs
IssuanceOfCommonStockAndWarrantsNetOfIssuanceCosts
75 usd
CY2023Q3 coep Shares Issued For Conversion Of Debt
SharesIssuedForConversionOfDebt
302926 usd
CY2023Q3 coep Shares Issued In Connection With Asset Purchase Agreement
SharesIssuedInConnectionWithAssetPurchaseAgreement
4320000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-6260907 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
5011641 usd
us-gaap Net Income Loss
NetIncomeLoss
-17242182 usd
us-gaap Net Income Loss
NetIncomeLoss
-34631239 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
750927 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
751038 usd
coep Gainloss On Change In Value Of Warrant Liability
GainlossOnChangeInValueOfWarrantLiability
-746625 usd
coep Gainloss On Change In Value Of Warrant Liability
GainlossOnChangeInValueOfWarrantLiability
0 usd
us-gaap Share Based Compensation
ShareBasedCompensation
348993 usd
us-gaap Share Based Compensation
ShareBasedCompensation
0 usd
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
3999614 usd
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
4620000 usd
coep Warrants Issued For Extinguishment Of Debt Cash Flow
WarrantsIssuedForExtinguishmentOfDebtCashFlow
0 usd
coep Warrants Issued For Extinguishment Of Debt Cash Flow
WarrantsIssuedForExtinguishmentOfDebtCashFlow
3408559 usd
coep Warrants Issued For Services
WarrantsIssuedForServices
2438026 usd
coep Warrants Issued For Services
WarrantsIssuedForServices
22475592 usd
coep Shares Issued In Connection With Asset Purchase Agreements
SharesIssuedInConnectionWithAssetPurchaseAgreements
4320000 usd
coep Shares Issued In Connection With Asset Purchase Agreements
SharesIssuedInConnectionWithAssetPurchaseAgreements
0 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-8075 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
8075 usd
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
-833 usd
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
0 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-76724 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-0 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-623 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
836 usd
us-gaap Increase Decrease In Other Accounts Payable
IncreaseDecreaseInOtherAccountsPayable
382983 usd
us-gaap Increase Decrease In Other Accounts Payable
IncreaseDecreaseInOtherAccountsPayable
193780 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
119193 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
161050 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5545728 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3028459 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 usd
coep Proceeds From Issuance Of Common Stock And Warrants Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCosts
3040935 usd
coep Proceeds From Issuance Of Common Stock And Warrants Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCosts
0 usd
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
374999 usd
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
300000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
500000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
3271485 usd
coep Shares Issued For Cash For Conversion Warrants
SharesIssuedForCashForConversionWarrants
0 usd
coep Shares Issued For Cash For Conversion Warrants
SharesIssuedForCashForConversionWarrants
5248324 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3165936 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
8219809 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-2379792 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
5191351 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3791302 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2179558 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1411510 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7370909 usd
us-gaap Interest Paid Net
InterestPaidNet
0 usd
us-gaap Interest Paid Net
InterestPaidNet
0 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 usd
coep Shares Issued In Exchange For Notes Receivable
SharesIssuedInExchangeForNotesReceivable
2500000 usd
coep Shares Issued In Exchange For Notes Receivable
SharesIssuedInExchangeForNotesReceivable
0 usd
coep Shares Issued For Conversion Of Debt
SharesIssuedForConversionOfDebt
302926 usd
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_84C_eus-gaap--UseOfEstimates_zqGaJcxsQTQi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_868_zdDLJxTZHre2">Use of Estimates</span> –</b> The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-82981905 usd
CY2023Q3 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
625000 usd
CY2023Q3 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
625000 usd
CY2023Q3 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
200000 usd
CY2023Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
625000 usd
CY2023Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
0 usd
CY2023Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
0 usd
CY2023Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
1687 usd
CY2023Q3 coep Long Term Debt Maturities Repayments Of Principal After Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFour
148313 usd
CY2023Q3 us-gaap Long Term Debt
LongTermDebt
975000 usd
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
0 usd
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
0 usd
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
32991036 shares
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
32991036 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
19566839 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
19566839 shares
us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
499950 usd
us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
3271444 usd
us-gaap Partners Capital Account Distributions
PartnersCapitalAccountDistributions
0 usd
us-gaap Partners Capital Account Distributions
PartnersCapitalAccountDistributions
0 usd
CY2023Q2 coep Warrants Issued
WarrantsIssued
2150000 shares
CY2023Q3 us-gaap Treasury Stock Value
TreasuryStockValue
0 usd
CY2022Q3 us-gaap Treasury Stock Value
TreasuryStockValue
0 usd
CY2023Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
1093448 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
33750 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
11250 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
18750 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
30000 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
4520 usd
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
25480 usd
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
28676 usd
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
10757 usd
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
14723 usd
CY2023Q3 coep Agreement Amendment Fee
AgreementAmendmentFee
2000 usd
CY2023Q3 us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
0 usd
CY2022Q3 us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
0 usd
us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
0 usd
us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
0 usd
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd

Files In Submission

Name View Source Status
0001683168-23-007828-index-headers.html Edgar Link pending
0001683168-23-007828-index.html Edgar Link pending
0001683168-23-007828.txt Edgar Link pending
0001683168-23-007828-xbrl.zip Edgar Link pending
coep-20230930.xsd Edgar Link pending
coeptis_ex3101.htm Edgar Link pending
coeptis_ex3102.htm Edgar Link pending
coeptis_ex3201.htm Edgar Link pending
coeptis_ex3202.htm Edgar Link pending
coeptis_i10q-093023.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
coep-20230930_def.xml Edgar Link unprocessable
coep-20230930_lab.xml Edgar Link unprocessable
coep-20230930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
coeptis_i10q-093023_htm.xml Edgar Link completed
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
coep-20230930_cal.xml Edgar Link unprocessable